Jobs
-
Chiesi Farmaceutici has submitted an MAA to the European Medicines Agency (EMA) for its extra-fine ICS/LABA/LAMA combination inhaler for the treatment of COPD. The submission is the first for a triple combination inhaler. In June… Read more . . .
-
Health Canada has approved Adapt Pharma’s Narcan naloxone nasal spray for reversal of known or suspected opioid overdose. The approval comes three months after Health Canada announced that it would allow importation of Narcan nasal… Read more . . .
-
OptiNose has appointed Tom Gibbs as Chief Commercial Officer to oversee the commercialization strategy for EDS-FLU (OPN-375) intranasal fluticasone, which is in Phase 3 development for the treatment of nasal congestion in patients with nasal… Read more . . .
-
Insmed has appointed Roger Adsett, a former global brand director for Symbicort, as its new Chief Commercial Officer in preparation for commercialization of Arikayce inhaled liposomal amikacin. Adsett also spent a portion of his time… Read more . . .
-
Mast Therapeutics has announced that it will stop its development program for vepoloxamer and will devote its resources to development of AIR001 sodium nitrite inhalation solution for patients with heart failure with preserved ejection fraction… Read more . . .
-
California-based simulation and modeling software company Simulations Plus has announced that it will join the SimInhale COST (European Cooperation in Science and Technology) Action consortium, which aims to “advance particle designs for improved deposition and… Read more . . .
-
The US Patent and Trademark Office (USPTO) has awarded US Patent No. 9,446,134 (“Stabilizing alkylglycoside compositions and methods thereof”) to Aegis Therapeutics, the company said. The patent covers an intranasal formulation of octreotide, which is… Read more . . .
-
According to an FDA drug shortages report, the US shortage of sumatriptan nasal spray due to a shortage of active ingredient that was first reported in November 2015 should be completely resolved by February 2017.… Read more . . .
-
According to Windtree Therapeutics, its Aerosurf inhaled lucinactant for the treatment of premature infants with respiratory distress syndrome (RDS) has received Fast Track designation from the FDA. Aerosurf is currently in Phase 2 development, with… Read more . . .
-
Purdue Pharma Canada will pay up to $3 million Canadian to Medical Developments International Limited (MDI) for Canadian rights to MDI’s Penthrox methoxyflurane inhaler for the treatment of moderate to severe pain in trauma patients,… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA